Rizatriptan 10 MG RPD in the Treatment of Acute Migraine (Rinotama)
This study has been completed.
Sponsor:
Universität Duisburg-Essen
Collaborator:
Merck
Information provided by (Responsible Party):
Hans-Christoph Diener, Universität Duisburg-Essen
ClinicalTrials.gov Identifier:
NCT01057160
First received: January 26, 2010
Last updated: January 25, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This is a multicentre, open label, prospective, randomized, two-attack study with active comparator in patients reporting inadequate response to analgesics and/or triptans to examine the efficacy of Rizatriptan 10 mg RPD in this group of patients.
| Condition | Intervention | Phase |
|---|---|---|
|
Migraine |
Drug: Rizatriptan |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Study of the Efficacy and Safety of Rizatriptan 10 mg RPD in the Treatment of Acute Migraine in Patients With Non Satisfactory Response to Previous Pharmacologic Treatment |
Resource links provided by NLM:
Further study details as provided by Universität Duisburg-Essen:
Primary Outcome Measures:
- Percentage of patients with headache response on a one to four scale after 2 hours. [ Time Frame: 2 hours ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Percentage of patients being headache free two hours after intake of study medication. Time of dosing to onset of headache relieve. Relief of concomitant symptoms. Rate of sustained pain free Percentage of patients needing rescue medication [ Time Frame: (time points 0.5, 1, 1.5, 2, 4, 8, 12, 24 hours after drug intake ] [ Designated as safety issue: No ]
| Enrollment: | 195 |
| Study Start Date: | May 2008 |
| Study Completion Date: | June 2010 |
| Primary Completion Date: | June 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: intake of rizatriptan 10 mg |
Drug: Rizatriptan
use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
|
| Active Comparator: previous used analgesic |
Drug: Rizatriptan
use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Patient's signature on the informed consent document [each patient should be given ample time to read (or have read to them) the consent form, ask any questions they may have regarding the trial and have a clear understanding of the trial and the procedures involved prior to the signing of the consent form].
- Have a clinical diagnosis of migraine with or without aura according to IHS criteria at least one year prior to enrollment.
- At screening at least two migraine attacks per month and no more than ten during the last three months prior to inclusion.
- At screening a stable dose of prophylactic medication (including no prophylactic treatment) for at least two months and no change of prophylactic medication during active trial period.
Exclusion Criteria:
- Contraindication to triptans or Rizatriptan according to medical information sheet.
- Patient has a history or clinical evidence of ischemic heart disease (e.g., angina pectoris of any type, history of myocardial infarction or documented silent ischemia) or symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm (including Prinzmetal's variant angina), or other significant underlying cardiovascular disease. Patient has uncontrolled hypertension. Patient has either demonstrated hypersensitivity to or experienced a serious adverse event in response to Rizatriptan or any of its inactive ingredients.
- History of treatment failure for at least one triptan for the treatment of acute migraine attacks.
- Any other headache, except tension type headache on 5 or less days a month within three months prior to screening.
- A history of drug induced headache, medication overuse headache or any other addiction.
- Any history of allergic hypersensitivity or poor tolerance to any components of the preparations used in this trial.
- Females of childbearing potential not using reliable means of birth control, pregnant or lactating females or expected/ planned pregnancy.
- Participation (planned or current) in any investigational drug or device trial within the previous 30 days prior to screening visit.
- Inability to understand the trial procedures, and thus inability to give informed consent.
- History of allergy to sulfa drugs.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01057160
Locations
| Germany | |
| Department of Neurology, University Hospital Essen | |
| Essen, Germany, 45147 | |
Sponsors and Collaborators
Universität Duisburg-Essen
Merck
Investigators
| Principal Investigator: | Hans-Christoph Diener, Prof. | Department of Neurology, University Essen |
More Information
No publications provided
| Responsible Party: | Hans-Christoph Diener, Prof. of Neurology, Universität Duisburg-Essen |
| ClinicalTrials.gov Identifier: | NCT01057160 History of Changes |
| Other Study ID Numbers: | MK 462 |
| Study First Received: | January 26, 2010 |
| Last Updated: | January 25, 2013 |
| Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
Additional relevant MeSH terms:
|
Migraine Disorders Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Rizatriptan |
Serotonin Receptor Agonists Serotonin Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Physiological Effects of Drugs |
ClinicalTrials.gov processed this record on June 18, 2013